Press releases and announcements from Fujirebio US

Researcher from Women & Infants'/Alpert Medical School Says Combination Tests Could Identify Women's Ovarian Cancer Risk for More Accurate Diagnosis, Treatment.

Fujirebio Diagnostics’ HE4 Granted CE Marking.

Combination of Tests Could Lead to Earlier Detection of the Silent Killer.

Malvern PA, USA - November 1, 2007: Company's MESOMARK® Test Recognized for Monitoring Patients with Asbestos-linked Cancer

See complete press release (PDF)

Malvern PA, USA - October 31 2007: Company to Develop HE4 for Screening, Detection, Monitoring and Prognosis of Disease

> See complete press release (PDF)



You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below: